Besides a few new treatment modalities that target at a cellular level to control the enzyme ALAS1’s activity, there is promising research ongoing that has the potential to revolutionize the treatment and long-term management of AIP. This evidence concerns the gene ALAS1 and autoimmune pancreatitis.